Neurology
Tau Is Back. Certainty Is Not.
Biogen’s diranersen data at AAIC show a serious tau-lowering signal in Alzheimer’s disease. They also show why biomarker enthusiasm still needs a harder clinical test.
Digital Mental Health Still Has an Evidence Problem
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
Europe’s Mental Health Projects Move From Crisis Talk to Delivery Tools
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
SMA Screening Shows Precision Neurology Starts Before Symptoms
Post-Stroke Cognitive Screening Needs Local Tools
Europe’s Stroke Plan Turns Speed Into a Policy Test
Parkinson’s Research Moves From Tracking Progression to Defining Biology
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.